EcoDrugPlus

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSDARG00000008388
Gene Symbol: MMP14B
5 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSDARG00000017676
Gene Symbol: MMP2
14 Enzyme and pathways 5 Cross references
210 Possible Orthologues:

Matrix Metallopeptidase 20a (Enamelysin)

Ensembl ID : ENSDARG00000089887
Gene Symbol: MMP20A
5 Cross references
165 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSDARG00000042816
Gene Symbol: MMP9
19 Enzyme and pathways 5 Cross references
216 Possible Orthologues:

Matrix Metalloproteinase-18-Like

Ensembl ID : ENSDARG00000108401
Gene Symbol: LOC101883213
5 Cross references
173 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSDARG00000053196
Gene Symbol: MTOR
32 Enzyme and pathways 5 Cross references
224 Possible Orthologues:

Melanocortin 1 Receptor

Ensembl ID : ENSDARG00000020237
Gene Symbol: MC1R
7 Enzyme and pathways 5 Cross references
159 Possible Orthologues:

Melanocortin 3 Receptor

Ensembl ID : ENSDARG00000021369
Gene Symbol: MC3R
7 Enzyme and pathways 5 Cross references
139 Possible Orthologues:

Melanocortin 4 Receptor

Ensembl ID : ENSDARG00000015515
Gene Symbol: MC4R
7 Enzyme and pathways 5 Cross references
211 Possible Orthologues:

Melatonin Receptor 1a A

Ensembl ID : ENSDARG00000037545
Gene Symbol: MTNR1AA
6 Enzyme and pathways 5 Cross references
190 Possible Orthologues:

Melatonin Receptor 1a B

Ensembl ID : ENSDARG00000055852
Gene Symbol: MTNR1AB
5 Cross references
138 Possible Orthologues:

Methionyl Aminopeptidase 2b

Ensembl ID : ENSDARG00000102571
Gene Symbol: METAP2B
7 Enzyme and pathways 5 Cross references
228 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).